Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq:ROIV) today reported its financial results for the third quarter ended December 31, 2022, and provided an update on the Company’s operations.
Related news for (ROIV)
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
- Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
- Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
- Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement